Literature DB >> 32769152

Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic.

Augustin Lecler1, Delphine Villeneuve2, Catherine Vignal3, Thomas Sené2.   

Abstract

Entities:  

Keywords:  giant cell arteritis; glucocorticoids; health services research

Mesh：

Substances：

Year:  2020        PMID： 32769152     DOI： 10.1136/annrheumdis-2020-218343

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  5 in total

1.  A Case of Giant Cell Arteritis With a Normal Erythrocyte Sedimentation Rate (ESR) Post ChAdOx1 nCoV-19 Vaccination.

Authors:  Chenfan Xia; Rachel Edwards; Bita Omidvar
Journal:  Cureus       Date:  2022-05-27

Review 2.  Looking ahead: giant-cell arteritis in 10 years time.

Authors:  Milena Bond; Alessandro Tomelleri; Frank Buttgereit; Eric L Matteson; Christian Dejaco
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-05-24       Impact factor: 3.625

Review 3.  Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective.

Authors:  Sarah L Mackie; Elisabeth Brouwer; Richard Conway; Kornelis S M van der Geest; Puja Mehta; Susan P Mollan; Lorna Neill; Michael Putman; Philip C Robinson; Sebastian E Sattui
Journal:  Lancet Rheumatol       Date:  2020-12-08

4.  Arteritic Anterior Ischemic Optic Neuropathy in the Course of Giant Cell Arteritis After COVID-19.

Authors:  Urszula Szydełko-Paśko; Joanna Przeździecka-Dołyk; Julia Kręcicka; Rafał Małecki; Marta Misiuk-Hojło; Anna Turno-Kręcicka
Journal:  Am J Case Rep       Date:  2022-01-11

Review 5.  Mimickers of Large Vessel Giant Cell Arteritis.

Authors:  André Ramon; Hélène Greigert; Paul Ornetti; Bernard Bonnotte; Maxime Samson
Journal:  J Clin Med       Date:  2022-01-19       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.